AFib Rhythm Control: 5-Year Outcomes Critically Reviewed
An evidence synthesis on EAST-AFNET 4, CABANA, and the early rhythm-control strategy in atrial fibrillation for internal medicine clinicians
One-Minute Takeaway on AFib Rhythm Control
One-Minute Takeaway
- EAST-AFNET 4 reframed AFib rhythm control by demonstrating that an early systematic strategy reduced cardiovascular events over a median 5.1-year follow-up in patients diagnosed within the prior year.
- Catheter ablation, particularly pulmonary vein isolation, has matured into a durable rhythm-control modality with consistent advantages over antiarrhythmic drugs for arrhythmia recurrence and quality of life.
- Patients with heart failure derive particularly clear benefit from rhythm restoration, supported by CASTLE-AF and the EAST-AFNET 4 heart-failure subgroup.
- Anticoagulation decisions are based on stroke risk (CHA2DS2-VASc), independent of rhythm-control success or perceived sinus rhythm restoration.
- Major evidence gaps remain around very long-term outcomes, ablation versus drugs in older or frailer patients, and head-to-head comparison of rhythm-control modalities.
Why AFib Rhythm Control Has Been Reframed
For two decades, the AFFIRM and RACE trials anchored clinical practice in the view that rate control was generally non-inferior to rhythm control for hard cardiovascular outcomes in atrial fibrillation. That framing was largely correct for the populations studied at the time, in which rhythm control depended on antiarrhythmic drugs initiated late in the disease course.
EAST-AFNET 4 (Kirchhof 2020) shifted this framing. By randomizing patients within one year of AFib diagnosis to early rhythm-control therapy or usual care, the trial demonstrated a reduction in the composite of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome over a median follow-up of 5.1 years.
In parallel, catheter ablation has matured. CABANA, EARLY-AF, STOP AF First, and CASTLE-AF have collectively positioned ablation as a durable rhythm-control modality, particularly when delivered early. For internists, AFib rhythm control is no longer a one-size-fits-all framework but a strategy that depends on disease duration, comorbidity, and shared decision-making.
The clinical question this review addresses: how should internal medicine clinicians integrate the EAST-AFNET 4 early rhythm-control strategy, catheter ablation evidence, and longstanding rate-control data into AFib rhythm control decisions for contemporary patients?
What Evidence Was Reviewed
This synthesis draws on the EAST-AFNET 4 trial and its prespecified subgroup analyses; the foundational AFFIRM and RACE rate-versus-rhythm comparisons; the CABANA randomized comparison of catheter ablation versus antiarrhythmic drugs; CASTLE-AF in heart failure; the early-ablation trials EARLY-AF and STOP AF First; and the 2023 ACC/AHA/ACCP/HRS and 2020 ESC AFib guidelines.
Studies were prioritized by design (RCT before observational), sample size, primary outcome relevance, and reproducibility across independent populations. Subgroup analyses were used to interpret heterogeneity, particularly in heart failure and asymptomatic patients.
| Study / Source | Design | n | Key Finding Relevant to AFib Rhythm Control |
|---|---|---|---|
| EAST-AFNET 4 (Kirchhof 2020) | Pragmatic RCT, AFib < 1 year | 2,789 | Early rhythm control reduced composite CV death/stroke/HF or ACS hospitalization (HR 0.79, 95% CI 0.66–0.94) |
| EAST-AFNET 4 HF subgroup (Rillig 2021) | Prespecified subgroup analysis | 798 | Benefit was preserved or amplified in patients with heart failure |
| EAST-AFNET 4 asymptomatic subgroup (Willems 2022) | Prespecified subgroup analysis | ~30% of cohort | Benefit was consistent in asymptomatic and symptomatic patients |
| CABANA (Packer 2019) | Phase 3 RCT, ablation vs drugs | 2,204 | Intention-to-treat analysis neutral; per-protocol and recurrence analyses favored ablation |
| CASTLE-AF (Marrouche 2018) | Phase 3 RCT in HFrEF + AFib | 363 | Catheter ablation reduced death or HF hospitalization (HR 0.62, 95% CI 0.43–0.87) |
| EARLY-AF (Andrade 2021) | Phase 3 RCT, first-line therapy | 303 | Cryoablation reduced atrial tachyarrhythmia recurrence vs antiarrhythmic drugs over 12 months |
| STOP AF First (Wazni 2021) | Phase 3 RCT, first-line therapy | 203 | Cryoballoon ablation as initial therapy improved rhythm outcomes |
| AFFIRM (Wyse 2002) | Phase 3 RCT, established AFib | 4,060 | Rate vs rhythm control with antiarrhythmic drugs neutral for survival |
| RACE (Van Gelder 2002) | Phase 3 RCT, persistent AFib | 522 | Rate control non-inferior to rhythm control for composite CV outcomes |
| AF-CHF (Roy 2008) | Phase 3 RCT in HF + AFib | 1,376 | Drug-based rhythm control did not reduce CV mortality in HFrEF |
| 2023 ACC/AHA/ACCP/HRS Guideline | Society guideline | NR | Early rhythm control as Class 2a; ablation Class 1 for symptomatic paroxysmal AFib failing antiarrhythmic drugs |
Key Findings on AFib Rhythm Control
EAST-AFNET 4 Reframed Early Rhythm Control
EAST-AFNET 4 randomized 2,789 patients with AFib diagnosed within the previous 12 months and at least one cardiovascular condition to either an early rhythm-control strategy (using antiarrhythmic drugs or catheter ablation) or usual care. Over a median follow-up of 5.1 years, the early-rhythm group had a 21% relative reduction in the primary composite of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome.
The absolute risk reduction was modest (3.9 events per 100 patient-years versus 5.0), but the trial was stopped early for efficacy. Importantly, anticoagulation continued throughout in both arms, and rate control was permitted as needed in either arm, isolating the effect of the rhythm-control strategy itself.
This stands in contrast to the older AFFIRM and RACE trials, which enrolled patients with longer-standing AFib and used antiarrhythmic drugs alone for rhythm control. The contemporary message is that AFib rhythm control offered EARLY (within the first year) and supported by safer drugs and ablation can produce meaningful event reduction.
Catheter Ablation as a Rhythm Control Modality
CABANA, the largest randomized trial of catheter ablation versus antiarrhythmic drugs, did not show significance for its primary intention-to-treat composite endpoint. Per-protocol and as-treated analyses favored ablation, and ablation consistently reduced AFib recurrence and improved quality of life across pre-specified secondary endpoints.
EARLY-AF and STOP AF First each demonstrated that cryoballoon ablation as first-line therapy reduced atrial tachyarrhythmia recurrence compared with antiarrhythmic drugs in patients with paroxysmal AFib. Both trials supported ablation as a reasonable initial option in selected patients without first failing pharmacotherapy.
The 2023 ACC/AHA/ACCP/HRS guideline reflects this evolution: catheter ablation carries a Class 1 recommendation for symptomatic paroxysmal AFib that has failed antiarrhythmic drugs and a Class 2a recommendation as first-line therapy in selected patients. Pulmonary vein isolation remains the cornerstone procedure.
Procedural Note
Modern pulmonary vein isolation can be performed with radiofrequency, cryoballoon, or pulsed-field ablation technologies. Pulsed-field ablation, an emerging non-thermal modality, has shown comparable efficacy with reduced collateral injury risk in early trials. Procedure-related complications include cardiac tamponade, pulmonary vein stenosis, and atrioesophageal fistula, all uncommon but clinically important.
Heart Failure: A Particular Beneficiary
The EAST-AFNET 4 prespecified heart-failure subgroup (Rillig 2021) included 798 patients and demonstrated that the benefit of early rhythm control was preserved or numerically amplified in this group. CASTLE-AF, an earlier RCT in patients with HFrEF and AFib, showed that catheter ablation reduced the composite of all-cause death or heart failure hospitalization compared with conventional therapy.
These findings sit alongside AF-CHF, which randomized patients with HFrEF and AFib to drug-based rhythm versus rate control and found no mortality difference. The reconciliation is that drug-only rhythm control may be insufficient or harmful in HFrEF, while ablation-based or modern combined rhythm strategies appear to provide meaningful benefit.
For patients with concomitant heart failure (HFrEF, HFmrEF, or HFpEF) and recent-onset or persistent AFib, rhythm restoration deserves serious consideration. Cardiology referral for ablation evaluation is reasonable, particularly when AFib appears to be driving heart failure decompensation.
The AFFIRM and RACE-era conclusion that rate control is non-inferior remains valid for many patients with longstanding AFib who are minimally symptomatic and lack heart failure. For these patients, lenient rate control (resting heart rate < 110 bpm) is reasonable and was supported by the RACE II trial.
However, for patients within the first year of AFib diagnosis, those with heart failure, those with bothersome symptoms, or those for whom AFib appears to be driving disease progression, contemporary evidence supports early rhythm control. The 2023 ACC/AHA/ACCP/HRS guideline operationalizes this distinction.
The decision is rarely binary. Many patients on rate control benefit from a trial of rhythm control if symptoms persist, and many patients on rhythm control settle into rate control after recurrence and symptom reassessment.
Antiarrhythmic drugs remain reasonable first-line therapy for many patients, particularly those without structural heart disease, where flecainide or propafenone are options, and those with structural heart disease, where amiodarone, dofetilide, or dronedarone may be considered.
Catheter ablation as first-line therapy is supported by EARLY-AF and STOP AF First in patients with paroxysmal AFib who prefer to avoid long-term drug therapy or whose comorbidity profile makes drugs less attractive. Ablation as first-line is a Class 2a recommendation in the 2023 guideline.
For paroxysmal AFib that has failed at least one antiarrhythmic drug, ablation is a Class 1 recommendation. For persistent AFib, ablation efficacy is lower but still favorable compared with continued drug therapy.
The EAST-AFNET 4 asymptomatic subgroup analysis (Willems 2022) showed that approximately 30% of enrolled patients were asymptomatic at baseline, and the early rhythm-control benefit was consistent across symptom status. This was an important finding because the symptom-driven framework of older trials may have understated benefit in this group.
Practically, identifying asymptomatic AFib who would otherwise be candidates for early rhythm control requires clinical vigilance and often pulse-check or ECG screening. In this population, the conversation about rhythm control is more nuanced and should weigh the absolute event reduction against procedural risks and drug burden.
Anticoagulation Decisions Sit Alongside, Not Within, Rhythm Strategy
A persistent point of confusion is whether successful rhythm restoration permits anticoagulation withdrawal. Current evidence and guidelines are clear that it does not. Stroke risk reduction with anticoagulation is determined by the CHA2DS2-VASc score and the presence of AFib in the history, not by current rhythm or perceived sinus rhythm restoration.
EAST-AFNET 4 explicitly continued anticoagulation in both arms throughout the trial. The 2023 ACC/AHA/ACCP/HRS guideline maintains anticoagulation indications based on stroke risk regardless of rhythm-control modality or success.
Discontinuation of anticoagulation post-ablation is an active area of investigation but should not occur outside a trial setting or specialty consultation in patients with elevated CHA2DS2-VASc scores.
Clinical Pearl: Anticoagulation, rhythm control, and rate control are independent decisions. A patient may receive a DOAC for stroke prevention, an antiarrhythmic for rhythm control, and a beta-blocker for rate control during recurrences — all simultaneously and all addressing different aspects of AFib management.
Quality & Consistency of Evidence
The contemporary AFib rhythm control evidence base combines a single large pragmatic trial of strategy (EAST-AFNET 4) with multiple device-versus-drug RCTs of varying size and follow-up. Heterogeneity arises in how rhythm control is operationalized, in the populations studied, and in the comparators used.
What the Evidence Does Not Show
Specific Evidence Gaps
Several clinically important questions about contemporary rhythm-control strategy remain unresolved. The named gaps below should shape patient counseling and ongoing trial design rather than be subsumed into a generic call for “more research.”
- Independent replication of EAST-AFNET 4. No second large pragmatic trial of early rhythm-control strategy has been published; replication would solidify the strategy’s evidentiary status.
- Outcomes beyond 5 to 7 years. Whether early rhythm-control benefit widens, narrows, or reverses with longer follow-up is not yet established.
- Ablation versus drugs in older or frailer patients. Trial populations have skewed younger and healthier than typical primary care AFib cohorts.
- Ablation versus drugs head-to-head with hard endpoints. CABANA’s intention-to-treat result was neutral; the per-protocol benefit may reflect crossover rather than true effect.
- Persistent and long-standing AFib. Ablation success rates are lower in these populations and the evidence for benefit is correspondingly less robust.
- Anticoagulation discontinuation after successful ablation. An active investigational question with no current adequate trial evidence.
Practical Implications for AFib Rhythm Control
Based on the current evidence, the following considerations represent areas where data are sufficiently consistent to inform routine internal medicine workflows. They are framed as evidence-supported considerations, not directive recommendations.
EAST-AFNET 4 supports an early systematic rhythm-control strategy in patients diagnosed within the previous 12 months and with cardiovascular risk factors, using antiarrhythmic drugs or ablation.
Evidence supports catheter ablation, particularly pulmonary vein isolation, for symptomatic paroxysmal AFib that has failed drugs and as a reasonable first-line option in selected patients.
CASTLE-AF and the EAST-AFNET 4 heart-failure subgroup support rhythm restoration in HF + AFib, with cardiology referral for ablation evaluation reasonable in many patients.
Stroke prevention is determined by CHA2DS2-VASc and AFib history, not current rhythm. Anticoagulation should not be withdrawn after successful rhythm restoration without specialty input.
Two further considerations complete the practical framework. Rate control remains entirely appropriate for many patients with longstanding, minimally symptomatic AFib without heart failure; lenient rate control (resting heart rate < 110 bpm) is supported by RACE II in stable patients. Risk-factor management — obesity, hypertension, sleep apnea, alcohol, and physical activity — complements pharmacologic and procedural rhythm strategies and is increasingly recognized as a fourth pillar of AFib care.
Evidence Grade & Bottom Line
Overall Evidence Grade: Moderate to Strong — The contemporary evidence base for early rhythm control and catheter ablation is robust for surrogate endpoints (recurrence, quality of life) and for the EAST-AFNET 4 composite endpoint over 5 years. Independent replication of the early-rhythm strategy and definitive ablation-versus-drug head-to-head comparisons remain limitations.
Bottom Line
- EAST-AFNET 4 demonstrated that early rhythm-control strategy reduces cardiovascular events over a median 5.1 years in patients diagnosed within the prior year.
- Catheter ablation, particularly pulmonary vein isolation, provides durable rhythm benefit and is a reasonable option as first-line therapy in selected patients.
- Heart failure patients derive particularly clear benefit from rhythm restoration, with both ablation and combined drug-ablation strategies supported by replicated evidence.
- Anticoagulation indications remain anchored to stroke risk via CHA2DS2-VASc, independent of current rhythm or rhythm-control success.
- Independent replication of the early rhythm-control strategy and ablation outcomes in older or frailer patients are key unresolved questions.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. DOI: 10.1056/NEJMoa2019422
- Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833. DOI: 10.1056/NEJMoa021328
- Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-1840. DOI: 10.1056/NEJMoa021375
- Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-1274. DOI: 10.1001/jama.2019.0693
- Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-427. DOI: 10.1056/NEJMoa1707855
- Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure. Circulation. 2021;144(11):845-858. DOI: 10.1161/CIRCULATIONAHA.121.056323
- Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022;43(12):1219-1230. DOI: 10.1093/eurheartj/ehab593
- Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021;384(4):305-315. DOI: 10.1056/NEJMoa2029980
- Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. 2021;384(4):316-324. DOI: 10.1056/NEJMoa2029554
- Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-2677. DOI: 10.1056/NEJMoa0708789
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. DOI: 10.1161/CIR.0000000000001193
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612
- Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation (RACE II). N Engl J Med. 2010;362(15):1363-1373. DOI: 10.1056/NEJMoa1001337